Clinicians’ Reports in Electronic Health Records Versus Patients’ Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin

Maxim Topaz (), Kenneth Lai, Neil Dhopeshwarkar, Diane L. Seger, Roee Sa’adon, Foster Goss, Ronen Rozenblum and Li Zhou
Additional contact information
Maxim Topaz: Brigham and Women’s Hospital
Kenneth Lai: Partners HealthCare System
Neil Dhopeshwarkar: Brigham and Women’s Hospital
Diane L. Seger: Brigham and Women’s Hospital
Roee Sa’adon: Treato Ltd.
Foster Goss: University of Colorado
Ronen Rozenblum: Brigham and Women’s Hospital
Li Zhou: Brigham and Women’s Hospital

Drug Safety, 2016, vol. 39, issue 3, No 6, 250 pages

Abstract: Abstract Introduction Large databases of clinician reported (e.g., allergy repositories) and patient reported (e.g., social media) adverse drug reactions (ADRs) exist; however, whether patients and clinicians report the same concerns is not clear. Objectives Our objective was to compare electronic health record data and social media data to better understand differences and similarities between clinician-reported ADRs and patients’ concerns regarding aspirin and atorvastatin. Methods This pilot study explored a large repository of electronic health record data and social media data for clinician-reported ADRs and patients concerns for two common medications: aspirin (n = 31,817 ADRs accessible in clinical data; n = 19,186 potential ADRs accessible in social media data) and atorvastatin (n = 15,047 ADRs accessible in clinical data; n = 23,408 potential ADRs accessible in social media data). Results We found that the most frequently reported ADRs matched the most frequent patients’ concerns. However, several less frequently reported reactions were more prevalent on social media (i.e., aspirin-induced hypoglycemia was discussed only on social media). Overall, we found a relatively strong positive and statistically significant correlation between the frequency ranking of reactions and patients’ concerns for atorvastatin (Pearson’s r = 0.61, p

Date: 2016
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-015-0381-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:39:y:2016:i:3:d:10.1007_s40264-015-0381-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-015-0381-x

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().